Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

The pathophysiology of major depressive disorder (MDD) is thought to result from impaired
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …

Importance Postpartum depression (PPD) is one of the most common medical complications
during and after pregnancy, negatively affecting both mother and child. Objective To …

Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive
steroid and GABA A receptor positive allosteric modulator, in major depressive disorder …

Positive allosteric modulators of γ-aminobutyric acid-A (GABA A) receptors or GABAkines
have been widely used medicines for over 70 years for anxiety, epilepsy, sleep, and other …

This article reviews novel neurosteroid therapeutics for post-partum depression, with a focus
on their development, clinical trial data, current practices, and future directions in this …

Abstract Zuranolone (SAGE-217) is a novel, synthetic, clinical stage neuroactive steroid
GABA A receptor positive allosteric modulator designed with the pharmacokinetic properties …

Major depressive disorder (MDD) is a common mental disorder with a high rate of morbidity
and mortality. Dysfunctional signaling of gamma-aminobutyric acid (GABA) has been …

Objective: Concurrent anxiety and/or insomnia symptoms in women with postpartum
depression (PPD) are common and associated with more severe PPD. The effects of …

Recent FDA approval of an allopregnanolone-based treatment specifically for postpartum
depression, brexanolone, now commercially called Zulresso®, is an exciting development …